harpoontx.com (HARP): חוב להון עצמי

Harpoon Therapeutics (HARP) is recognized as a leader in the targeted destruction of solid tumors thanks to innovative T-cell engagers. This price chart illustrating trading dynamics demonstrates a debt-to-equity metric of 3.04. Technological development relies on a strategic alliance with AbbVie to create new therapeutic methods. High interest from Big Pharma led to the acquisition of the business to globally implement its developments.

For Harpoon Therapeutics (HARP), which is protected by patents for trispecific antibodies and backed by a pharma behemoth, this indicator determines the extent of development dependence on borrowed funds relative to equity. By analyzing the total debt-to-equity ratio, an investor assesses the risk of excessive leverage or, conversely, an investment deficit, which, combined with the company's financial shield, confirms its resilience against FDA regulatory barriers.